Report of the Trustees and Financial Statements for the Year Ended 31 March 2024 

Patron: His Majesty King Charles III | Vice President: His Royal Highness The Duke of Gloucester Registered Charity Number 213251 (England and Wales) SC039715 (Scotland) Registered company number 324748 

1 



## **Lepra (limited by guarantee)** 

## **CHAIR AND CHIEF EXECUTIVE’S REPORT** 

This year, we don’t just look back on what Lepra achieved in the past twelve months, but over an entire century working at the forefront of care, treatment and support for thousands upon thousands of people in the world affected by leprosy and lymphatic filariasis (LF). 

Lepra turned 100 years old on 31st January, 2024 and we are proudly celebrating our rich tapestry of a history – from our inception in 1924, through our early decades as the British Empire Leprosy Relief Association (BELRA), to our work supporting trials for the first drug to successfully cure leprosy, to our re-naming as Lepra, and across the years to now: here in 2024. 

A centenary is no small thing. As the Lepra UK Chair and CEO, we are proud and privileged to stand on the shoulders of all those who have gone before us and who built the organisation that we are part of today. It is an honour to be leading the organisation at this momentous time in our history. 

We take pride in Lepra’s heritage, but we are also acutely aware of how much more needs to be done. 

Leprosy still exists. LF still exists. Millions of people still live with the lifelong impacts of both. 

So as we reflect on our past one hundred years, 2024 has also been a time for us to take stock of where we are going as well as where we have come from. We are determined to build on the successes of the past, and further our work in the years ahead. We know we have more to give to support people affected by leprosy and LF in the world. 

Over the past months we have been planning for the future and are delighted to have introduced our new Global Strategy for 2024-2030. The strategy has been developed by staff and Trustees in all three countries where we work – Bangladesh, India and the UK – and it charts out how Lepra can support accelerated progress for the care, treatment and support for people affected by leprosy and LF in the years ahead. 

Our new Global Strategy will ensure that we stay true to Lepra’s roots and heritage. We will always place the needs of people affected by leprosy and LF at the forefront of all that we do – as we have always done. And as we celebrate our hundred years, we know that we would be doing something wrong if Lepra was still around for anything like a hundred more. Our Global Strategy helps us to look ahead with clarity of purpose, and keep working towards a world where we are needed no more. 





Suzanne McCarthy Chair of the Trustees 

Jimmy Innes Chief Executive 

2 



## **Lepra (limited by guarantee)** 

## **REPORT OF THE TRUSTEES AND STRATEGIC REPORT** 

**The Trustees submit their report and the audited financial statements for the year ended 31 March 2024.** 

The consolidated financial statements have been prepared under the accounting policies set out in Note 2 of the financial statements. These have been prepared in accordance with the Memorandum and Articles of Association and the Charities Statement of Recommended Practice 2019 (FRS102). 

For the purposes of the Companies Act 2006, the Board of Trustees is the Board of Directors of the charitable company and is referred to as the “Trustees” throughout this report. As required by the constitution, the Trustees are also members of the organisation. The Trustees and Officers of Lepra during the period and to the date of signing this report are as follows: 

## **Trustees** 

Mrs S McCarthy (Chair) 

Mrs S Bhasin 

Ms K Bigmore 

Mr D Dhamija (resigned 8[th] November 2023) 

Prof. R Hay 

Mr V Katoch (resigned 1st February 2024) 

Mr N Patel (resigned 1[st] February 2024) 

Mr N Raynaud 

Mr S Sharma 

Mr N Solanki (appointed 8th October 2024) 

Mr N Thapar (resigned 16[th] May 2023) 

Mr L Thomas 

Dr S Walker 

Mrs K Crabtree 

## **Officers** 

Chief Executive Officer: 

Mr J Innes 

Company Secretary: 

Mr N Avery 

## **Bankers** 

Barclays Bank UK PLC, 9 High Street, Colchester, Essex, CO1 1DD 

Metrobank PLC, 31-32 High Street, Colchester, Essex, CO1 1DB 

## **Auditors:** 

Crowe U.K.LLP, 4th Floor, St James House, St James Place, Cheltenham, GL50 3PR 

## **Principal Office:** 

28 Middleborough, Colchester, CO1 1TG 

3 



Our Trustee Board is responsible and accountable for Lepra. They do this, by setting the strategy and ensuring good governance, legal and ethical compliance. This year the Trustees have especially focused on governance, the continuance of the 3 year joint strategic plan for the period 1 April 2021 – 31 March 2024 (deferred from 2020 due to COVID-19), income generation, and safeguarding. 

The work of the Board of Trustees is supported by three standing Sub-Committees; 

## **Audit Finance and Risk Sub-Committee** 

Mrs S Bhasin (Chair) Mrs S McCarthy Mr N Raynaud 

## **Fundraising and Communications Sub-Committee** 

Mr S Sharma (Chair) Mrs S McCarthy Mr N Patel 

Mr L Thomas 

Mrs K Crabtree 

## **Technical Advisory Sub-Committee** 

Mr R Hay (Chair) Ms D Lockwood (co-opted member following retirement) Mr S Walker 

Ms M Rao (co-opted member) 

Each Sub-Committee has clear term of reference and is additionally attended by the Chief Executive, the relevant Senior Management Team member and other staff, as agreed by the Sub-Committee’s Chair. The Board and each Sub-Committee meet formally at least four times each year. The agendas for the Board and SubCommittees are set in an annual calendar which itself is reviewed at each meeting of the Board. A Nominations Sub-Committee is convened by the Board Chair for the recruitment of new Trustees and the Chief Executive, the composition at any time being determined by the recruitment task. 

A scheme of delegation is in place, which specifies those matters reserved for the Board and those matters delegated to the Sub-Committees or to the Chief Executive. The terms of reference of the Sub-Committees were reviewed and updated during 2023. The Board retains responsibility for the charity’s strategy, annual plan and budget, and the monitoring of these.  The annual plan and budget are the principal means by which implementation of the strategy is delegated to the Chief Executive who is accordingly responsible for the day - to -day running of the charity and, where appropriate, the delegation of budget and operational responsibility to members of the Senior Management Team. 

The remuneration of all key management personnel is determined by the Board, on the recommendation of the Audit Finance and Risk Sub-Committee. In setting the level of remuneration, the Board takes account of available job market and macro-economic data as well as the charity’s financial position. The Charity has subscribed to a job evaluation and remuneration benchmarking service to inform its decision making. 

The Board has benchmarked its governance processes against the Charity Governance Code annually since the current code was introduced in December 2020. The Board considers that it is substantially compliant with the code, although it has identified the need for better processes around equality, diversity and inclusion and has embarked upon a project to bring Lepra’s processes in line with sector best practices, including appropriate training and revised recruitment processes. The Trustee Board attended a full day session in May 2023, where they reflected on their effectiveness and agreed an action plan focused on improvements. 

Trustees are recruited in the light of the skills mix and overall diversity of the Board. Trustee roles are advertised publicly with a clear job and person specification and are shortlisted and interviewed by the Nominations Sub- 

4 



Committee. The Board is responsible for appointing Trustees, in accordance with the Article of Association by ordinary resolution and are advised by the Nominations Sub-Committee in this matter. The appointment is confirmed by resolution at the first available general meeting. Trustee terms are determined by the Trustee Terms of Office policy, which currently allows Trustees to serve three terms of three years each. 

The Board has changed in composition during the year as a result of resignations due to personal circumstances and upcoming retirements. All of the Trustees have been carefully selected and offer valuable experience, knowledge and insight from their field, as well as being passionate about our goals. During 2023/2024 the board is undertaking a skills and experience audit to ensure that a sufficiently diverse range of skills and perspectives exist to enable the board to be effective.  Our Trustees volunteer their time and energy towards helping us beat leprosy together. 

New Trustees are required to sign the Lepra Global Code of Conduct and are subject to appropriate criminal records checks. They receive a formal induction in which they receive safeguarding training as well as information about the role of a Trustee both generally and specifically at Lepra. Where possible Trustees visit offices and engage with staff both in the UK and overseas to understand the charity’s operations and strategy. 

## **GOVERNING DOCUMENT** 

Lepra is a charitable company limited by guarantee, founded in 1924, incorporated on 26 February 1937 and registered as a charity on 4 February 1963. It was established under the Memorandum of Association which established its objects and powers and is governed under its Articles of Association. The Memorandum and Articles of Association were amended by Special Resolutions of the Trustees on 4 June 1957, 7 June 1967, 24 September 1970, 1 July 2008, 15 May 2013, 27 September 2016, 1 October 2019 and 6 May 2022. 

The majority of our programmes are delivered through our own operations in Bangladesh, which is a branch office of the charity which is also registered with the NGO Bureau in Bangladesh and in India through Lepra Society which is a separate charity registered under the Societies Registration Act and Foreign Contribution (Regulation) Act under Indian law. The Lepra Society has an independent Board as required by local legislation. The Trustees believe however that Lepra Society is controlled by the UK charity in accordance with the definitions in FRS102 (Charity SORP) and is therefore considered a subsidiary entity and Lepra therefore prepares group accounts into which the financial results of Lepra Society are consolidated. 

## **PUBLIC BENEFIT STATEMENT** 

Lepra’s objects are contained within the Articles of Association, they are: 

“To carry out the investigation of and promote research into the causes, treatment, cure and prevention of the disease of leprosy and any allied disease, and give and grant relief and assistance to any persons suffering or believed to be suffering from, or the family or dependents of such persons of any description, including financial assistance.” 

The articles also grant the charity power to do anything which is calculated to further its Objects(s) or is conducive or incidental to doing so. 

The objects of the charity are reviewed in each iteration of our Joint Strategic Plan (JSP), which is a triennial process. It remains the case that social, mental, and physical health outcomes for many people affected by leprosy and lymphatic filariasis (LF), are significantly poorer than for other treatable conditions. Many of those who have developed disabilities as a result of untreated leprosy or LF have poor socioeconomic outcomes. Our research and programmes are designed to improve outcomes at all stages from prevention through to physical, psychological, social and economic care and support. In our current Joint Strategic Plan 2021-2024, we are investing heavily in improving our monitoring of outcomes and impacts. These are reported externally informally through our quarterly newsletters to donors, and more formally in our Annual Review. 

We monitor progress against the delivery of the Joint Strategic Plan through an annual business plan, in which agreed charity objectives are set. Progress against these objectives is measured at Trustee Board and Senior Management Team meetings. 

The Trustees, from time to time, consider the relevance of Lepra’s objects and whether and how the charity might continue in the future if its Objects were no longer relevant. 

5 



The Trustees are therefore confidently able to state that Lepra has complied with Section 17 of the Charities Act 2011, having due regard to the public benefit guidance issued by the Charity Commission. The Trustees have consulted and adhered to the Commission’s advice, specifically PB1, PB2 and PB3 for the year 2023/24. 

6 



## **OUR STRATEGY AND FUTURE PLANS** 

This year marked the end of one global strategy and the beginning of another. Over the course of the year our teams in the UK, India and Bangladesh invested significant collective time and thought into shaping and honing our new plan for the future. The result is a robust and ambitious strategy, which sets our direction over the next six years 2024-30 and clarifies how we can accelerate our contribution for the improved care, treatment of support for people affected by leprosy and LF. 

The new Global Strategy elevates LF to an equal footing with leprosy at the Vision and Overall Impact level. Until now, Lepra has always been a leprosy organisation that also works on LF: from now on now, Lepra is a leprosy and LF organisation. 

The strategy targets are all about health, inclusion and innovation for people affected by leprosy and LF. 

The health focus builds on what we already do well. We have a long track record in healthcare service provision for people affected by leprosy and LF and it will continue to be a cornerstone of our work. 

The inclusion focus accelerates our work on addressing stigma and discrimination, as well as supporting the empowerment, quality of life and wellbeing for people affected by leprosy and LF – placing them at the forefront, and amplifying their voice and agency to realise full inclusion and equality in society. 

The innovation focus enables us to test and trial new ways of caring, treating and supporting people affected by leprosy and LF. There has been so much progress in care and treatment for people affected by leprosy and LF over the past decades, but more needs to be done to support the millions of people still affected. 

Our renewed focus on innovation and research also reconnects us with our past, and our proud history of research and innovating for better care and treatment. 

Another key aspect of the new Global Strategy is a focus on what we call the One Lepra approach. Lepra is a global family that is united across its three countries of operation. The spirit of One Lepra runs through our DNA and is a bedrock of our organisational culture. 

In the new Global Strategy, we are cementing our spirit of One Lepra in a Partnership Agreement between the two autonomous and independent organisations of LEPRA Society in India and Lepra UK (which includes Lepra Bangladesh) as a statement of commitment and responsibility to each other about how we work and liaise together in a partnership of equals for our work on leprosy and LF. 

LEPRA Society and Lepra UK have co-developed the Global Strategy and now embark on a transformative agenda to strengthen the organisational capacity of LEPRA Society over the next six years so that it can take on more global leadership for One Lepra in the long-term. 

This is a significant strategic commitment, the rationale for which is simple: we want to ensure we have maximum impact for people affected by leprosy and LF, and in order to do so, we want our resources, skills and expertise – our organisational capacity – to be closer to the people who we exist to serve. 

## **FUNDRAISING PRACTICES STATEMENT** 

All fundraising was undertaken by staff employed by Lepra as Lepra does not engage third party professional fundraisers to fundraise on its behalf. We do not fundraise via outbound telephone or face to face canvassing, and thus are able to exercise control over the risks of donors or potential donors suffering unreasonable pressure and persistence. 

The finance team who process donations, including inbound telephone donations, are aware of the risks around vulnerable donors. We make cancelling regular payments and receipt of newsletters as easy as possible for our supporters. All staff are required to comply with our Ethical Fundraising policy. 

The Chief Executive and all staff are actively engaged in diversifying Lepra’s income sources with specific responsibility assigned to the Director of Fundraising and Communications. 

7 



Lepra is registered with the Fundraising Regulator and has paid the levy thus demonstrating our commitment to good fundraising practice, including ensuring awareness of the need to protect vulnerable donors in line with our safeguarding policy. 

We have committed to abide by the Code of Fundraising Practice and the Fundraising Promise meaning that we commit to high standards, will be clear, honest and open, be respectful, be fair and reasonable and be accountable and responsible. 

All staff, volunteers and Trustees are briefed on the latest version of the Code of Fundraising Practice and compliance is part of relevant staff member’s personal objectives. 

All volunteers, staff and Trustees are obliged to sign and commit to honouring Lepra’s Global Code of Conduct which defines expectations of exemplary behaviour. 

We have an open complaints process, which governs all Lepra staff, volunteers, donors and supporters and is published on our website. During this financial year there were two complaints received about our fundraising practices one which was resolved within the financial year and the other in the following year. 

Review of fundraising income generation and expenditure and of relevant policies is conducted jointly by the Audit, Finance and Risk Sub-Committee and the Fundraising and Communications Sub-Committee. 

8 



## **PRINCIPAL RISKS AND UNCERTAINTIES** 

The Board of Trustees is responsible for the management of risks and is assisted by the Senior Management Team (SMT) in the day- to -day management of all risks. A strategic risk register is maintained and used to examine and monitor the more significant risks to the organisation. 

The Board delegates the more detailed scrutiny of risk management activity to the Audit, Finance and Risk SubCommittee who review risks quarterly. The full Board reviews the strategic risk register annually and always has access to it. 

Lepra reports risk evaluation and mitigation over three main categories. 

- Strategic risk 

- Operational risk 

- Financial risk 

Within these risk categories, risks are reported in accordance with the approach recommended by the Charity Commission guidance (CC26). Risks may be articulated with financial, reputational or environment impacts, or with a combination of impacts. 

## **Fundraising and impact of inflation on the cost base** 

The key risk to Lepra remains the reliance on unrestricted fundraising and legacies to fund its programming, advocacy and research. The risk of inflating costs outweighing increases in income is likely to be an issue both for Lepra and for its many generous donors. Whilst we hold reserves to protect against short term fluctuations in unrestricted income, we also have detailed plans for sustaining our unrestricted income in the longer term, with a particular focus on donor acquisition and diversification of income streams. 

## **Ability to continue our operations in India** 

Lepra Society registration under the Foreign Contributions (Regulation) Act 2020 in India was renewed for five years with effect from 1[st] October 2023 with the result that this risk is now very significantly reduced. This is in no small part due to significant efforts on the part of the India team to ensure compliance with the complex requirements of this legislation. 

## **Ability to demonstrate Impact** 

We believe that there are improvements to be made in the quality of our impact data which will better allow us to demonstrate our impact to donors. This is an issue that is by no means unique to Lepra and is a clear focus for our current global strategy in general and our UK and overseas programmes teams specifically.  Lepra remains short of where it needs to be and continues to invest in a range of projects to achieve sustainable improvements. 

## **Safeguarding issues** 

A safeguarding system failure could have a serious impact upon our beneficiaries and would cause significant reputational damage to Lepra. We have adopted the best practices recommended by the Charity Commission and the Foreign, Commonwealth and Development Office and as such have embedded safeguarding into our operations and governance. The best systems and policies cannot eliminate the possibility of safeguarding issues arising and the importance of identifying and dealing with issues is key. We have updated and improved our policies and processes, including our training and reporting frameworks during 2023.  We have since nominated safeguarding focal points in all countries of operation.  We have provided training to our teams in India and Bangladesh. We also have designated safeguarding trustees in all our countries of operation including a standardised annual safeguarding work plan, which is developed every year. 

## **Fraud risk** 

Offline and online fraud are ever-present risks to charities throughout the delivery chain, and difficult economic environments always lead to an increase in fraud risk generally. The relatively small size of the UK charity creates dependence on a few key individuals, and internal audit processes are being developed that will provide assurance that risk mitigation is optimised.  Globally, we continue to work with our global teams to ensure that transparency and accountability is embedded across the organisation. 

9 



## **Operations in Bangladesh** 

Operations in Bangladesh have since improved with the recruitment of the new leadership team.  In addition to this, we have introduced new policies to strengthen accountability.   We continue to seek support from specialist tax advisors to ensure that we continue to adhere to local regulatory compliance. 

## **CONTROLS** 

The Trustees have overall responsibility for ensuring that the organisation has appropriate systems of control, financial and otherwise. They are responsible for keeping proper accounting records which disclose, with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the Financial Statements comply with the FRS 102 SORP and Companies Act 2006. 

The Trustees recognise that systems of control can only provide a reasonable and not complete assurance against inappropriate or ineffective use of resources, or against the risk of errors or fraud. They remain satisfied that the internal systems provide reasonable assurance that the organisation operates efficiently and effectively, safeguards its assets, maintains proper records and complies with relevant laws and regulations. 

We operate a comprehensive accountability system which includes an annual budget approved by the Trustees. The budget and any subsequent reforecasts are reviewed by the Audit Finance and Risk Sub-Committee and they consider actual results compared with plans and non- financial performance data. 

In 2024/25, our key focus area is around legal compliance and fraud and the introduction of an assurance map. This will help to identify areas where we need more assurance about control effectiveness across such risks. Lepra UK lacks the scale necessary for a dedicated internal audit function within the UK office, we are however working with our peers in Bangladesh and India to develop a peer review process across all operations, expanding on that which already exists in India. We will also seek independent assurance on a case by case basis as and when the need arises. 

## **RESERVES** 

We hold reserves as a key part of our strategic risk mitigation. Our reserves policy is approved each year by the Trustees as part of our annual planning and budgeting process. 

## **What is our safe level of unrestricted reserves?** 

In order to ensure that colleagues in India and Bangladesh can maintain and develop infrastructure, we commit to a certain level of funding when the annual plan is agreed in February each year. This is largely funded out of that year’s unrestricted income. We hold £400k of UK charity reserves to cover volatility in unrestricted fundraising, particularly around legacies and the considerable risks to our fundraising from a rapidly deteriorating economic outlook. 

## **Designation of reserves to support the Global Strategy plan** 

The delivery of our Global Strategy Plan required an annual drawdown of £200k from unrestricted reserves. The Board agreed to designate unrestricted reserves of £400k to support the strategy. The designation is to cover the additional costs of implementing the plan compared to the recurrent expenditure inherent in programme delivery. A significant deficit budget was approved by the board in 2024 for the delivery of the global strategy for 2024-29. 

## **Designation of unrestricted funds** 

We designated £225k of unrestricted reserves to the ASPIRE project in 2020/21, a five-year collaboration with Effect Hope aimed at reducing the incidence and impact of a number of neglected tropical skin diseases, including Leprosy and LF, in Bihar, India. A formal agreement to this effect was signed by both parties on 1st July 2021. The balance of this fund at the end of the year was £92k. 

Against this total UK Charity reserves requirement of £400k, the free reserves of the UK Charity were £620k at 31st March 2024. The group free reserves were £1,815k the additional reserves held by Lepra Society equating to approximately 12 months’ running costs, providing a contingency buffer against any difficulties experienced remitting funding from the UK to India. 

10 



## **GOING CONCERN** 

Lepra’s current and forecasted unrestricted reserves and cash position is above the target levels set out in the reserves policy and our generation of unrestricted funding has remained robust. The Trustees have a reasonable expectation, that the Charity has adequate resources to continue operating for the foreseeable future, thus they continue to adopt the going concern basis in preparing the financial statements. 

## **GRANT MAKING POLICY** 

Lepra works principally through its branch in Bangladesh and its subsidiary, The Lepra Society in India. In addition, payments are made to other charities in relation to joint projects and collaborations. The funding for all these projects is approved by the Board when it approves the annual budget. Consequently, unsolicited applications for grants are not invited from other organisations. 

## **INVESTMENTS POLICY** 

Lepra seeks the best returns on investment commensurate with its risk appetite. The investment objective for short term funds is to preserve capital value with minimal risk and a plan is in the process of implementation to meet this objective. Assets should be readily realisable to meet unanticipated cash requirements in excess of planned expenditure. 

A small portfolio of investments is held in accordance with powers of the Trustees. Investments are either listed or readily realisable and acquired through generous donation from our supporters with the exception of unlisted shares in Helpcards Holdings Ltd in which Lepra holds 6.74% of the issued share capital. Except for the investment in Helpcards Holdings Ltd, which is a strategic investment, the Trustees have authorised the disposal of all readily realisable equity investments at the earliest opportunity, subject to cost. 

## **SAFEGUARDING POLICY** 

Lepra promotes best practice in safeguarding its beneficiaries, staff and volunteers. A Trustee and executive director are designated with responsibility for safeguarding, and it is a standing item on all Board and Senior Management Team meeting agendas. All staff, Trustees and volunteers are subject to appropriate checks, are required to sign the Global Code of Conduct and receive safeguarding training. This is supported with robust complaints and whistleblowing policies. There have been no reported safeguarding incidents against Lepra staff during 2023/2024 however, there was one concern reported against third party care givers which Lepra took steps to address. 

## **DATA PROTECTION POLICY** 

Lepra has robust policies and procedures to protect and control personal data of donors, supporters and employees. Specific policies govern the handling of personal data and use of IT systems with monitoring of compliance with the Data Protection Act 2018. All staff and volunteers are trained in data protection during induction 

11 



## **FINANCIAL REVIEW** 

Total income for the year ended 31 March 2024 was £4.9m, a decrease of £452k compared to prior year. This is largely due to a decrease in legacies income.  Excluding legacies, unrestricted income increased by £59k. 

Unrestricted income for the charity excluding legacies increased by £48k in total compared to the prior year, which was due to an increase in  Trusts & Corporate, Community and Events.  There was a slight increase in individual giving income of about £35k. 

Overall, the group’s unrestricted income reduced by £62k reflecting both tough economic conditions and staff turnover. 

Restricted income, at £1.67m was down by £11k compared to prior year.  This is largely due to reduced income from funding agencies. 

Despite the challenging economic circumstances that many of our donor’s face, we remain humbled by their continuing support and the generosity of their bequests. 

Total expenditure from unrestricted funds was £3.5m, an increase of £404k compared to prior year. This is expected due to the investment in the country programmes in both India and Bangladesh as part of the global strategic plan. 

Overall, a group deficit of £332k on unrestricted funds was generated and this was partly due to foreign exchange losses. Group cash decreased by £665k. 

Group cash balances at year end were £1.6m and Group Funds were £5.39m. 

## **STATEMENT OF TRUSTEES’ RESPONSIBILITIES** 

The Trustees (who are also directors of Lepra under company law) are responsible for preparing the annual report (including strategic report) and the financial statements in accordance with applicable laws and regulations. 

Company law requires Trustees to prepare financial statements in accordance with UK Generally Accepted Accounting Practice which give a true and fair view of the state of affairs of the company and of the incoming resources and application of resources, including income and expenditure for that period. In preparing these financial statements, the Trustees are required to: 

- Select suitable accounting policies and apply them consistently; 

- Observe methods and principles in the Charities’ SORP; 

- Make judgements and estimates that are reasonable and prudent; 

- State whether applicable UK Accounting Standards have been followed, subject 

- to any material departures disclosed and explained in the financial statements; and 

- Prepare the financial statements on a going concern basis unless it is inappropriate to presume that the company will continue in business. 

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, and the Charities Accounts (Scotland) Regulations 2006 (as amended). 

They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. 

Legislation in the UK governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 

In so far as the Trustees are aware: 

12 



- There is no relevant audit information of which the company’s auditor is unaware and 

- The Trustees have each taken all steps that they ought to have taken as a Trustee in order to make them aware any relevant audit information, and to establish that the company’s auditors are aware of that information. 

Approved by the Board of Trustees on 3[rd] December 2024 including in their capacity as company directors the strategic report contained therein and signed on its behalf by: 

Suzanne McCarthy Chair 




Lepra (Company no 324748) 

13 



**INDEPENDENT AUDITOR’S REPORT TO THE TRUSTEES AND MEMBERS OF LEPRA** 

## **Opinion** 

We have audited the financial statements of Lepra (‘the charitable company’) and its subsidiaries (‘the group’)] for the year ended 31 March 2024 which comprise Consolidated Statement of Financial Activities, Consolidated Balance Sheet, Consolidated Cash Flow Statement, Charity Statement of Financial Activities, Charity Balance Sheet, Charity Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). 

In our opinion the financial statements: 

- give a true and fair view of the state of the group’s and the charitable company’s affairs as at 31 March 2024 and of the group’s income and expenditure, for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005 and Regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (amended). 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's or the group’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

14 



We have nothing to report in this regard. 

## **Opinions on other matters prescribed by the Companies Act 2006** 

In our opinion based on the work undertaken in the course of our audit 

- the information given in the trustees’ report, which includes the directors’ report and the strategic 

- report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the strategic report and the directors’ report included within the trustees’ report have been prepared 

- in accordance with applicable legal requirements. 

## **Matters on which we are required to report by exception** 

In light of the knowledge and understanding of the group and charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors’ report included within the trustees’ report. 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion: 

- adequate and proper accounting records have not been kept; or 

- the financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of trustees' remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit. 

## **Responsibilities of trustees** 

As explained more fully in the trustees’ responsibilities statement set out on page 12, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. 

## **Auditor’s responsibilities for the audit of the financial statements** 

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder. 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below. 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. 

Extent to which the audit was considered capable of detecting irregularities, including fraud 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team members. We then designed and performed audit 

15 



procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion. 

We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006 and The Charities and Trustee Investment (Scotland) Act 2005 together with the Charities SORP (FRS102) 2019. We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items. 

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company’s and the group’s ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and the group for fraud. The laws and regulations we considered in this context for the UK operations were Anti-fraud, bribery and corruption legislation, taxation legislation. We also considered compliance with local legislation for the group’s overseas operating segments. 

Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any. 

We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the timing of recognition of grant and legacy income and the override of controls by management. Our audit procedures to respond to these risks included enquiries of management, and the Audit, Finance & Risk Committee about their own identification and assessment of the risks of irregularities, performing sample testing on grant and legacy income, sample testing on the posting of journals, reviewing accounting estimates for biases, reviewing regulatory correspondence with the Charity Commission, OSCR, and reading minutes of meetings of those charged with governance. 

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations. 

16 



## **Use of our report** 

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company’s trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body and the charitable company’s trustees as a body, for our audit work, for this report, or for the opinions we have formed. 


## **Tara Westcott** 

Senior Statutory Auditor For and on behalf of Crowe U.K. LLP Statutory Auditor 4th Floor St James House St James Square Cheltenham, GL50 3PR Date: 20 December 2024 

17 



## **Lepra** 

## **CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES** 

**YEAR ENDED 31 MARCH 2024** 

|Note<br>**Income from:**<br>Donations and legacies<br>6<br>Charitable activities<br>6<br>Investments<br>6<br>Other<br>6<br>**Total income**<br>**Expenditure on:**<br>Raising funds<br>8<br>Charitable activities<br>8<br>**Total expenditure**<br>Net gains / (losses) on<br>investments<br>12<br>**Net income /**<br>**(expenditure)**<br>**Transfers between**<br>**funds**<br>18<br>**Other recognised gains /**<br>**(losses):**<br>(Losses)/Gains on foreign<br>currency transactions<br>**Total other**<br>**(Losses)/Gains**<br>**Net movement in funds**<br>**Reconciliation of funds:**<br>Total funds brought<br>forward<br>**Total funds carried**<br>**forward**|**Unrestricted**<br>**Funds**<br>**Restricted**<br>**Funds**<br>**Designated**<br>**Funds**<br>**Total**<br>**2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>3,028,043<br>126,176<br>-<br>3,154,219<br>138,603<br>1,540,579<br>-<br>1,679,182<br>76,915<br>-<br>-<br>76,915<br>22,408<br>-<br>-<br>22,408<br>3,265,969<br>1,666,755<br>-<br>4,932,724<br>478,732<br>-<br>-<br>478,732<br>3,022,326<br>1,649,112<br>59,023<br>4,730,461<br>3,501,058<br>1,649,112<br>59,023<br>5,209,193<br>14,797<br>-<br>-<br>14,797<br>(220,292)<br>17,643<br>(59,023)<br>(261,672)<br>-<br>-<br>-<br>-<br>(70,188)<br>-<br>-<br>(70,188)<br>(70,188)<br>-<br>-<br>(70,188)<br>(290,480)<br>17,643<br>(59,023)<br>(331,860)<br>4,984,386<br>187,528<br>550,548<br>5,722,462<br>4,693,906<br>205,171<br>491,525<br>5,390,602|**Unrestricted**<br>**Funds**<br>**Restricted**<br>**Funds**<br>**Designated**<br>**Funds**<br>**Total**<br>**2023**<br>**£**<br>**£**<br>**£**<br>**£**<br>3,590,070<br>58,474<br>-<br>3,648,544<br>2,265<br>1,619,565<br>-<br>1,621,830<br>91,451<br>-<br>-<br>91,451<br>23,265<br>-<br>-<br>23,265|
|---|---|---|
|||3,707,051<br>1,678,039<br>-<br>5,385,090<br>377,000<br>-<br>-<br>377,000<br>2,720,390<br>1,660,252<br>55,733<br>4,436,375|
|||3,097,390<br>1,660,252<br>55,733<br>4,813,375<br>(1,601)<br>-<br>-<br>(1,601)|
|||608,060<br>17,787<br>(55,733)<br>570,114<br>-<br>-<br>-<br>-<br>(81,993)<br>-<br>-<br>(81,993)|
|||(81,993)<br>-<br>-<br>(81,993)|
|||526,067<br>17,787<br>(55,733)<br>488,121<br>4,458,319<br>169,741<br>606,281<br>5,234,341<br>4,984,386<br>187,528<br>550,548<br>5,234,341|



All gains and losses arising in the year are included above and arise from continuing actives. 

The notes on pages 24- 49 form part of these financial statements. Company registration number:00324748 

18 



## **Lepra** 

**CONSOLIDATED BALANCE SHEET Company registration number 00324748 YEAR ENDED 31 MARCH 2024** 

|**Note**<br>**FIXED ASSETS**<br>Tangible assets<br>9<br>Investment Property<br>10<br>Intangible assets<br>11<br>Investments<br>12<br>**CURRENT ASSETS**<br>Stocks<br>14<br>Debtors<br>15<br>Investments<br>Cash at bank and in hand<br>**CREDITORS:**<br>Amounts falling due within one year<br>16<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**<br>**CREDITORS:**<br>Amounts falling due after more than one<br>year<br>16<br>**TOTAL NET ASSETS**<br>**FUNDS**<br>Unrestricted funds – general<br>18<br>Unrestricted funds – designated<br>20<br>Restricted funds<br>19|**£**<br>30,975<br>449,645<br>631,342<br>1,639,137|**2024**<br>**£**<br>2,517,743<br>283,770<br>10,219<br>66,494|**2023**<br>**£**<br>**£**<br>2,266,525<br>214,715<br>28,724<br>68,874<br>2,578,838<br>25,022<br>410,068<br>626,144<br>2,304,095<br>3,365,329<br>(221,705)<br>3,143,624<br>5,722,462<br>-<br>5,722,462<br>4,984,386<br>550,548<br>187,528<br>5,722,462|**2023**<br>**£**<br>**£**<br>2,266,525<br>214,715<br>28,724<br>68,874<br>2,578,838<br>25,022<br>410,068<br>626,144<br>2,304,095<br>3,365,329<br>(221,705)<br>3,143,624<br>5,722,462<br>-<br>5,722,462<br>4,984,386<br>550,548<br>187,528<br>5,722,462|
|---|---|---|---|---|
|||2,878,226||2,578,838|
||2,751,099<br>(238,723)||3,365,329<br>(221,705)||
|||2,512,376||3,143,624|
|||5,390,602<br>-||5,722,462<br>-|
|||5,390,602||5,722,462|
|||4,693,906<br>491,525<br>205,171||4,984,386<br>550,548<br>187,528|
|||5,390,602||5,722,462|



The financial statements were approved by the Trustees and authorised for issue on 3[rd] of December 2024. 


Mrs S Bhasin, Hon Treasurer 

The notes on pages 24-49 form part of these financial statements. 

19 



## **Lepra** 

## **CONSOLIDATED CASH FLOW STATEMENT** 

|**YEAR ENDED 31 MARCH 2024**<br>**Statement of cash flows**<br>**Cash flows from operating activities:**<br>**Net cash used in operating activities**<br>**Cash flows from investing activities:**<br>Dividends and interest<br>Proceeds from the sale of fixed assets<br>Purchase of fixed assets<br>Proceeds from the sale of investments<br>Purchase of investments<br>Net cash used in investing activities<br>**Cash flows from financing activities:**<br>Repayments of borrowing<br>Net cash used in financing activities<br>Change in cash and cash equivalents<br>Opening cash and cash equivalents<br>Change in cash and cash equivalents due to exchange rate movements<br>**Cash and cash equivalents at 31 March**<br>Reconciliation of net income (expenditure) to net cash flow from operating activities:<br>Net income (expenditure) for the period (as per SOFA)<br>Adjustments for:<br>Depreciation charges<br>(Gains)/losses on investments<br>Dividends and interest<br>Loss/(profit) on sale of fixed assets<br>(Increase)/decrease in stocks<br>Foreign exchange difference on opening reserves<br>(Increase) in debtors<br>(Increase) in short term investments<br>Increase in creditors<br>**Net cash used in operating activities**|**2024**<br>**2023**<br>**£**<br>**£**<br> (134,589)<br>507,991|
|---|---|
||76,915<br>91,451<br>-<br>-<br>(537,096)<br>(347,201)<br>-<br>-<br>-<br>(1,161)|
||(460,181)<br>(256,911)|
||-<br>(327,214)|
||-<br>(327,214)|
||(594,770)<br>(76,134)<br>2,304,095<br>2,462,222<br>(70,188)<br>(81,993)|
||1,639,137<br> 2,304,095|
||2024<br>2023<br>£<br>£<br>(261,672)<br>570,114<br>247,804<br>220,726<br>(15,736)<br>1,601<br>(76,915)<br>(91,451)<br>3,760<br>7,341<br>(5,953)<br>(4,197)<br>3,101<br>-<br>(39,577)<br>(164,333)<br>(5,198)<br>(54,128)<br>15,797<br>22,318|
||(134,589)<br>507,991|



20 



**Lepra** 

## **CHARITY STATEMENT OF FINANCIAL ACTIVITIES** 

## **YEAR ENDED 31 MARCH 2024** 

|Note<br>**Income from:**<br>Donations and legacies<br>6<br>Charitable activities<br>6<br>Investments<br>6<br>Other<br>6<br>**Total income**<br>**Expenditure on:**<br>Raising funds<br>8<br>Charitable activities<br>8<br>**Total expenditure**<br>Net gains / (losses) on<br>investments<br>12<br>**Net income /**<br>**(expenditure)**<br>**Transfers between**<br>**funds**<br>18<br>**Other recognised gains /**<br>**(losses):**<br>Gains (Losses) on foreign<br>currency transactions<br>**Total other gains /**<br>**(losses)**<br>**Net movement in funds**<br>**Reconciliation of funds:**<br>Total funds brought<br>forward<br>**Total funds carried**<br>**forward**|**Unrestricted**<br>**Restricted**<br>**Designated**<br>**Total**<br>**Funds**<br>**Funds**<br>**Funds**<br>**2024**<br>**£**<br>**£**<br>**£**<br>1,747,229<br>105,263<br>-<br>1,852,492<br>138,602<br>246,158<br>-<br>384,760<br>13,017<br>-<br>-<br>13,017<br>22,408<br>-<br>-<br>22,408<br>1,921,256<br>351,421<br>-<br>2,272,677<br>478,732<br>-<br>-<br>478,732<br>1,976,688<br>374,558<br>59,023<br>2,410,269<br>2,455,420<br>374,558<br>59,023<br>2,889,001<br>14,797<br>-<br>-<br>14,797<br>(519,367)<br>(23,137)<br>(59,023)<br>(601,527)<br>-<br>-<br>-<br>-<br>(34,550)<br>-<br>-<br>(34,550)<br>(34,550)<br>-<br>-<br>(34,550)<br>(553,917)<br>(23,137)<br>(59,023)<br>(636,077)<br>2,370,530<br>46,566<br>550,548<br>2,967,644<br>1,816,613<br>23,429<br>491,525<br>2,331,567|**Unrestricted**<br>**Funds**<br>**Restricted**<br>**Designated**<br>**Total**<br>**2023**<br>**Funds**<br>**Funds**<br>**£**<br>**£**<br>**£**<br>2,329,375<br>58,474<br>-<br>2,387,849<br>-<br>346,998<br>-<br>346,998<br>21,004<br>-<br>-<br>21,004<br>23,265<br>-<br>-<br>23,265|
|---|---|---|
|||2,373,644<br>405,472<br>-<br>2,779,116<br>377,000<br>-<br>-<br>377,000<br>1,845,730<br>408,061<br>55,733<br>2,309,524|
|||2,222,730<br>408,061<br>55,733<br>2,686,524<br>(1,601)<br>-<br>-<br>(1,601)|
|||149,313<br>(2,589)<br>(55,733)<br>90,991<br>-<br>-<br>-<br>-<br>(31,164)<br>-<br>-<br>(31,164)|
|||(31,164)<br>(31,164)|
|||118,149<br>(2,589)<br>(55,733)<br>59,827<br>2,252,381<br>49,155<br>606,281<br>2,907,817<br>2,370,530<br>46,566<br>550,548<br>2,967,644|



All gains and losses arising in the year are included above and arise from continuing activities. 

The notes on pages 24-49 form part of these financial statements 

21 



## **Lepra** 

## **CHARITY BALANCE SHEET** 

**Company registration number 00324748 YEAR ENDED 31 MARCH 2024** 

|**Note**<br>**FIXED ASSETS**<br>Tangible assets<br>9<br>Investment Property<br>10<br>Intangible assets<br>11<br>Investments<br>12<br>**CURRENT ASSETS**<br>Debtors<br>15<br>Cash at bank and in hand<br>**CREDITORS:**<br>Amounts falling due within one year<br>16<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT LIABILITIES**<br>**CREDITORS:**<br>Amounts falling due after more than one year<br>16<br>**TOTAL NET ASSETS**<br>**FUNDS**<br>Unrestricted funds - general<br>18<br>Unrestricted funds - designated<br>20<br>Restricted funds<br>19|**2024**<br>**£**<br>**£**<br>860,550<br>283,770<br>10,186<br>40,977<br>1,195,483<br>122,894<br>1,148,472<br>1,271,366<br>(135,282)<br>1,136,084<br>2,331,567<br>-<br>2,331,567<br>1,816,613<br>491,525<br>23,429<br>2,331,567|**2024**<br>**£**<br>**£**<br>860,550<br>283,770<br>10,186<br>40,977<br>1,195,483<br>122,894<br>1,148,472<br>1,271,366<br>(135,282)<br>1,136,084<br>2,331,567<br>-<br>2,331,567<br>1,816,613<br>491,525<br>23,429<br>2,331,567|**2023**<br>**£**<br>**£**<br>929,106<br>214,715<br>28,668<br>42,418<br>1,214,907<br>198,283<br>1,760,689<br>1,958,972<br>(206,235)<br>1,752,737<br>2,967,644<br>-<br>2,967,644<br>2,370,530<br>550,548<br>46,566<br>2,967,644|**2023**<br>**£**<br>**£**<br>929,106<br>214,715<br>28,668<br>42,418<br>1,214,907<br>198,283<br>1,760,689<br>1,958,972<br>(206,235)<br>1,752,737<br>2,967,644<br>-<br>2,967,644<br>2,370,530<br>550,548<br>46,566<br>2,967,644|
|---|---|---|---|---|
|||1,195,483||1,214,907|
||1,271,366<br>(135,282)||1,958,972<br>(206,235)||
|||1,136,084||1,752,737|
|||2,331,567<br>-||2,967,644<br>-|
|||2,331,567||2,967,644|
|||1,816,613<br>491,525<br>23,429||2,370,530<br>550,548<br>46,566|
|||2,331,567||2,967,644|



The financial statements were approved by the Trustees and authorised for issue on 3[rd] of December 2024 


Mrs S Bhasin Hon Treasurer 

The notes on pages 24-49 form part of these financial statements. 

22 



## **Lepra** 

## **CHARITY CASH FLOW STATEMENT** 

## **YEAR ENDED 31 MARCH 2024** 

|**Statement of cash flows**<br>**Cash flows from operating activities:**<br>**Net cash used in operating activities**<br>**Cash flows from investing activities:**<br>Dividends and interest<br>Proceeds from the sale of fixed assets<br>Purchase of fixed assets<br>Proceeds from the sale of investments<br>Purchase of Investments<br>Net cash used in investing activities<br>**Cash flows from financing activities:**<br>Repayments of borrowing<br>Net cash used in financing activities<br>Change in cash and cash equivalents<br>Opening cash and cash equivalents<br>Change in cash and cash equivalents due to exchange rate movements<br>**Cash and cash equivalents at 31 March**<br>Reconciliation of net income (expenditure) to net cash flow from operating activities:<br>Net income (expenditure) for the period (as per SOFA)<br>Adjustments for:<br>Depreciation charges<br>(Gains)/losses on investments<br>Dividends and interest<br>Decrease/(increase) in debtors<br>Increase/(decrease) in creditors<br>**Net cash used in operating activities**|**2024**<br>**2023**<br>£<br>£<br>(574,367)<br>102,937|
|---|---|
||13,017<br>21,004<br>-<br>-<br>(16,317)<br>(16,512)<br>-<br>-<br>-<br>-|
||(3,300)<br>4,492|
||-<br>(327,214)|
||-<br>(327,214)|
||(577,667)<br>(219,785)<br>1,760,689<br>2,011,638<br>(34,550)<br>(31,164)|
||1,148,472<br>1,760,689|
||2024<br>2023<br>£<br>£<br>(601,527)<br>90,991<br>50,538<br>58,116<br>(14,797)<br>1,601<br>(13,017)<br>(21,004)<br>75,389<br>(61,277)<br>(70,953)<br>34,510|
||(574,366)<br>102,937|



23 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

## **YEAR ENDED 31 MARCH 2024** 

- 1 STATUS 

The Company is limited by guarantee and has no share capital.  The liability of each member is determined by the constitution of the Association and shall not exceed the sum of £1. The charity was incorporated in the United Kingdom, registered office is 28 Middleborough, Colchester, CO1 1TG. Charity number 213251. Company registration number 00324748. 

- 2 ACCOUNTING POLICIES 

   - a) The financial statements have been prepared under the historical cost convention. The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charitable Company is a public benefit company for the purposes of FRS 102 and therefore the Charity also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011. 

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the charity and group to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. During the financial year, the charity has continued to show the resilience of its unrestricted income streams, and whilst the current economic environment is challenging, we have significant cash and unrestricted reserves and our operations in the UK and in India and Bangladesh are sufficiently scalable to respond to unforeseen reductions in income. The Trustees believe that over a 1-2 year timescale, release of cash reserves, our unrestricted fundraising donor base, our legacy pipeline and ability to scale back programming operations together provide a reasonable expectation that the charity and group has adequate resources to continue in operational existence for the foreseeable future. The charity and group therefore continues to adopt the going concern basis in preparing its financial statements. 

- b) Quoted fixed asset investments are recorded on the Balance Sheet at bid price values at the year end. The unquoted investments are recorded at the valuation determined by the Trustees. 

- c) Realised gains and losses arising from the disposal of fixed asset investments are calculated as the difference between the net sale or redemption proceeds and either the market value at the last balance sheet date or the cost of investments purchased during the year. 

- d) Unrealised gains and losses arising on the revaluation of fixed asset are considered immaterial and are taken straight to the unrestricted reserves rather than via a specific revaluation reserve. 

- e) Income recognition - Income tax recoverable on gift-aided donations is calculated and accrued based upon income received during the financial year. Legacies are recognised at the earlier of the point that estate accounts have been received, or the cash has been received. 

   - Under this accounting policy, in the absence of payment, legacies are only accrued on receipt of finalised estate accounts or where it is judged that there is sufficient other evidence that the legacy can be reliably estimated. Reversionary interests involving a life tenant and discretionary trusts are not recognised. 

Donations are reported on a receivable basis. 

Grants receivable where related to performance and specific deliverables, is accounted for as the Charity earns the right to consideration by its performance. Where Income is received in advance of performance, its recognition is deferred and included in creditors. Where entitlement occurs before income is received, the income is accrued. 

- f) Resources expended are allocated to the particular activities where the cost relates directly to that activity. Support Costs are allocated as the costs that are identified as a direct support to an activity. The activities and allocations included resources expended was updated last year to better reflect how the charity now receives income and the work that we do. Central costs are apportioned on a staff time basis as follows: Programmes 49.17%, Research 1.67%, Advocacy 11.04%, Education 10.42%, Leprosy Review 3.73% Database Fundraising 16.88%, Events 2.92% and Institutions & Trusts 4.17%. 

24 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

- g) Property that is held for long-term rental or is being developed for future rental is classified as investment property. The fair value of the land and buildings is determined by a market-based appraisal undertaken by a professionally qualified valuer every three years and the next valuation will be undertaken in 2024 to reflect changes in license to occupy footage. Changes in fair value are recognised in the Statement of Financial Activity. Assets are reviewed annually for any impairment in value. 

- h) All assets purchased are valued at cost. UK assets purchased below £500 are not capitalised and are shown as a revenue cost. 

Depreciation is charged on the Organisation’s fixed assets at the following rates, which are expected to reduce the assets to their net realisable values over their estimated useful lives. 

|Freehold Building||Over 50 years|
|---|---|---|
|Motor vehicles||25% per annum on cost|
|Office equipment||20% per annum on cost|
|Computer equipment||25% per annum on cost|
|LEPRA India|Leasehold|Over the life of the lease|
||Freehold Buildings|10%|
||Vehicles and equipment|15%|
||Medical equipment|15%|
||Furniture|10%|
||Computer equipment|40%|
||Intangible Assets|25%|



Depreciation is provided for the full year on the written down value method, at the above rates as prescribed in the Indian Income Tax Act, 1961. 

|LEPRA Bangladesh|Furniture|15% per annum reducing balance|
|---|---|---|
||Office equipment|15% per annum reducing balance|
||Bicycle|20% per annum reducing balance|
||Motor vehicles/cycles|<br>20% per annum reducing balance|
||Computer equipment|33% per annum reducing balance|



- i) Freehold property at 28 Middleborough, Colchester CO1 1TG was purchased on 4 November 2004. This, together with the contracted works, has been fully recognised in the accounts. 

- j) Computer software is stated at cost less accumulated amortisation and accumulated impairment losses. Computer software is amortised over its estimated useful life of 4 years, on a straight-line basis. 

- k) Other financial instruments 

   - i. Cash and cash equivalents: Cash and cash equivalents include cash at banks and in hand and short-term deposits with a maturity date of three months or less. 

   - ii. Debtors and creditors: 

      - Debtors and creditors receivable or payable within one year of the reporting date are carried at the at transaction price. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest. 

- l) Foreign currency balances have been converted at the exchange rate ruling at 31 March 2024. Transactions during the year are included at the average rate for the year in which the transaction occurred. With regard to the accounts of overseas branch and subsidiary undertakings these are translated into sterling on the following basis: 

   - Assets and liabilities are at the rate of exchange ruling at the year-end date. 

   - Income and Expenditure account items at the average rate of exchange for the year. 

   - All exchange differences arising on the translation into sterling are recognised through the Statement of Financial Activities. 

25 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

- m) Grant expenditure on programmes and research is accounted for in the period when payable and sums unpaid at the balance sheet date are included in current liabilities. 

- n) Deferred income relates to income received during the financial year which has been restricted by the donor to be spent in a future accounting period. 

- o) Critical accounting estimates and areas of judgement–- in the view of the trustees in applying the accounting policies adopted, an accounting estimate is applied to the legacy accrual (£2,821) as legacies are accrued based on estate accounts. An accounting judgement is taken on whether the charity is entitled to grant income received in the year (£384,760). 

- p) Lepra operates a defined contribution pension scheme for its employees. The contributions are paid monthly as they fall due. The expense to activity allocation matches the wage to activity allocation. Pension costs are treated as unrestricted unless a specific restricted gift was received for that purpose. 

- q) Fund accounting Funds held by the charity are: 

Unrestricted general funds – these are funds that can be used in accordance with the charitable objects at the discretion of the Trustees. 

Restricted funds – these are funds that can only be used for a particular purpose within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for specific restricted purposes. 

Designated funds – these are funds which have been designated for specific purposes by the Lepra Trustees. 

Further explanations of the nature and purpose of each fund is included in the notes to the accounts. 

- r) Stock is valued at the lower of cost or net realisable value. 

- s) Current asset investments consist of short-term deposits with a maturity date of more than 3 months but less than 12 months. Any deposits with a maturity date of more than 12 months are included within fixed asset investments. 

- t) Donated services and facilities relate to medical equipment provided to Lepra Society India and are valued at cost price. 

- u) Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight-line basis over the lease term. 

## **4 BASIS OF CONSOLIDATION** 

The Group financial statements consolidate the financial statements of the Charity and its subsidiary undertaking for the year. Lepra (Society) India is consolidated in these financial statements as a subsidiary.  Lepra (Society) India is considered to be a subsidiary, within the requirements outlined in SORP FRS102 section 24.16, because Lepra has the power to govern financial and operating policies as set out in specific clauses included within the Lepra (Society) India memorandum and, in the event of dissolution, remaining assets will be transferred to Lepra. 

All financial statements are made up to 31 March 2024. All intra-group transactions, balances and unrealised gains on transactions between group entities are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Where necessary, adjustments are made on consolidation to bring the accounting policies used into line with those used by other members of the group. 

Lepra Bangladesh is treated as a branch of Lepra and forms part of the Charity financial statements. 

The summary financial statements of Lepra India are shown in Note 5. 

26 



**Lepra** 

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

**YEAR ENDED 31 MARCH 2024** 

## **5          SUBSIDIARIES SUMMARY FINANCIAL STATEMENTS** 

## **LEPRA SOCIETY OF INDIA** 

Lepra has common objects and activities to the “LEPRA Society of India” (hereafter called LEPRA India).  LEPRA India is a registered charity, Charity Registration number 474 of 1989 under the Andhra Pradesh Public Societies Registration Act 1350 Fasli and having its offices at Plot No 17, Krishnapuri Colony, West Marredpally, Secunderabad 500-026, India **.** 

The Chairman of the Organisation’s Trustees and of its Medical Advisory Board, plus the Chief Executive of LEPRA UK are exofficio members of the Management Committee of LEPRA India.  LEPRA India determines its own policies governing its leprosy control and related work in India and is free to raise funds in India in future; but currently, and for the foreseeable future, LEPRA India is dependent on Lepra for its funding support under a mutually agreed annual budget. 

## **LEPRA INDIA INCOME & EXPENDITURE ACCOUNT** 

|**LEPRA INDIA INCOME & EXPENDITURE ACCOUNT**||||
|---|---|---|---|
|Income:<br>Grants from UK<br>Other income<br>Expenditure:<br>(Losses)/gains on foreign currency translation<br>Net movement in funds<br>Balance at 31 March 2024<br>Corpus Fund<br>Balance at 31 March 2024<br>**LEPRA INDIA BALANCE SHEET**<br>Tangible Fixed Assets<br>Fixed Asset Investment<br>Current Assets<br>Investments<br>Stock<br>Debtors<br>Cash at bank & in hand<br>Creditors: Amounts falling due within one year<br>SER Revolving Fund<br>Restricted Fund<br>Capital & Corpus Fund|**2024**<br>**£**<br>**£**<br>920,524<br>2,639,133<br>3,559,657<br>(3,240,715)<br> (35,639)<br>283,303<br>2,754,818<br>20,913<br>3,059,034<br>**£**<br>**£**<br>1,657,252<br>25,517<br>631,342<br>30,975<br>326,729<br>490,665<br>1,479,711<br>(86,459)<br>(16,982)<br>1,376,270<br>3,059,034<br>140,962<br>2,918,072<br>3,059,034|**2023**<br>**£**<br>**£**<br>958,550<br>2,605,974<br>3,564,524<br>(3,085,401)<br> (50,830)<br>428,293<br>2,326,525<br>2,754,818<br>**£**<br>**£**<br>1,337,475<br>26,456<br>626,144<br>25,022<br>211,785<br>543,406<br>1,406,357<br>1,512<br>(16,982)<br>1,390,887<br>2,754,818<br>140,962<br>2,613,856<br>2,754,818||
||||3,564,524<br>(3,085,401)<br> (50,830)|
||||428,293<br>2,326,525|
||||2,754,818|
||||**£**<br>1,337,475<br>26,456<br>1,390,887|
||1,479,711<br>(86,459)<br>(16,982)|1,406,357<br>1,512<br>(16,982)||
|||||
||||2,754,818|
||||140,962<br>2,613,856|
||||2,754,818|



27 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **6 ANALYSIS OF INCOME** 

|**Consolidated**|**Note**|**Unrestricted**<br>**Funds**|**Restricted**<br>**Funds**|**Total**<br>**2024**|**Unrestricted**<br>**Funds**|**Restricted**<br>**Funds**|**Total**<br>**2023**|
|---|---|---|---|---|---|---|---|
|||**£**|**£**|**£**|**£**|**£**|**£**|
|**Donations and legacies**||||||||
|Community||110,959|2,000|112,959|143,325|-|143,325|
|Individual giving||1,969,306|-|1,969,306|1,934,573|-|1,934,573|
|Legacies|27|889,860|-|889,860|1,390,241|-|1,390,241|
|Events||16,338|-|16,338|23,796|-|23,796|
|Trusts & Corporate||41,580|124,176|165,756|98,135|58,474|156,609|
|||3,028,043|126,176|3,154,219|3,590,070|58,474|3,648,544|
|**Charitable activities**||||||||
|Programme funding||138,603|1,502,114|1,640,717|2,265|1,586,254|1,588,519|
|Leprosy Review funding||-|38,465|38,465|-|33,311|33,311|
|||138,603|1,540,579|1,679,182|2,265|1,619,565|1,621,830|
|**Other**||||||||
|Other income||20,642|-|20,642|20,623|-|20,623|
|Leprosy Review||1,766|-|1,766|2,642|-|2,642|
|||22,408|-|22,408|23,265|-|23,265|
|**Investments**||76,915|-|76,915|91,451|-|91,451|
|**Total income**||3,265,969|1,666,755|4,932,724|3,707,051|1,678,039|5,385,090|



The legacy income accrual reflected in the above figures is based on income outstanding for those estates where we have received approved estate accounts.  The accrual at the 31st of March 2024 on £2,821 (£95,016 on 31st March 2023). 

28 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **ANALYSIS OF INCOME** 

|**Charity**<br>**Note**<br>**Donations and**<br>**legacies**<br>Community<br>Individual giving<br>Legacies<br>27<br>Events<br>Trusts & Corporate<br>**Charitable activities**<br>Programme funding<br>Leprosy Review funding<br>**Other**<br>Sale of fixed assets<br>Government Grants<br>Other income<br>Leprosy Review<br>**Investments**<br>**Total income**|**Unrestricted**<br>**Funds**<br>**£**<br>110,959<br>688,492<br>889,860<br>16,338<br>41,580<br>1,747,229<br>138,602<br>-<br>138,602<br>-<br>-<br>20,642<br>1,766<br>22,408<br>13,017<br>1,921,256|**Restricted**<br>**Funds**<br>**£**<br>2,000<br>-<br>-<br>-<br>103,263<br>105,263<br>207,693<br>38,465<br>246,158<br>-<br>-<br>-<br>-<br>-<br>-<br>351,421|**Total**<br>**2024**<br>**£**<br>112,959<br>688,492<br>889,860<br>16,338<br>144,843<br>1,852,492<br>346,295<br>38,465<br>384,760<br>-<br>-<br>20,642<br>1,766<br>22,408<br>13,017<br>2,272,677|**Unrestricted**<br>**Funds**<br>**£**<br>**Restricted**<br>**Funds**<br>**£**<br>143,325<br>-<br>673,878<br>-<br>1,390,241<br>-<br>23,796<br>-<br>98,135<br>58,474<br>2,329,375<br>58,474<br>-<br>313,687<br>-<br>33,311<br>-<br>346,998<br>-<br>-<br>-<br>-<br>20,623<br>-<br>2,642<br>-<br>23,265<br>-<br>21,004<br>-<br>2,373,644<br>405,472|**Total**<br>**2023**<br>**£**<br>143,325<br>673,878<br>1,390,241<br>23,796<br>156,609|
|---|---|---|---|---|---|
|||||2,329,375|2,387,849|
|||||-<br>-<br>-<br>-<br>-<br>20,623<br>2,642<br>23,265<br>21,004<br>2,373,644|313,687<br>33,311|
||||||346,998|
||||||-<br>-<br>20,623<br>2,642|
||||||23,265|
||||||21,004|
||||||2,779,116|



The legacy income accrual reflected in the above figures is based on income outstanding for those estates where we have received approved estate accounts.  The accrual on 31st March 2024 was £2,821 (£95,016 on 31st March 2023). 

29 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **7 INVESTMENT INCOME** 

## **Consolidated** 

Investment income comprises interest and dividends received in respect of: 

|Investment income comprises interest and dividends received in respect of:||
|---|---|
|Dividends from quoted UK investments<br>Dividends from unquoted UK investments<br>Interest on short term deposits|**2024**<br>**2023**<br>**£**<br>**£**<br>938<br>8,527<br>-<br>7,414<br>75,977<br>75,510|
||76,915<br>91,451|



## **Charity** 

Investment income comprises interest and dividends received in respect of: 

|Dividends from quoted UK investments<br>Dividends from unquoted UK investments<br>Interest on short term deposits|**2024**<br>**2023**<br>**£**<br>**£**<br>938<br>8,527<br>-<br>7,414<br>12,079<br>5,063|
|---|---|
||13,017<br>21,004|



30 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **8      ANALYSIS OF EXPENDITURE** 

|**Consolidated**<br>**a) Activity**<br>Programmes<br>Research<br>Advocacy<br>Education<br>Leprosy<br>Review<br>**Charitable**<br>**Activities**<br>Database<br>Fundraising<br>Events<br>Trust &<br>Corporate<br>**Cost of**<br>**Generating**<br>**Funds**<br>**Total**<br>**Expenditure**|<br>**Direct**<br>**Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2024**<br>**Direct Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2023**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>4,125,161<br>207,857<br>76,261<br>4,409,279<br>3,874,603<br>206,346<br>59,004<br>4,139,953<br>9,021<br>13,406<br>2,590<br>25,017<br>9,094<br>13,613<br>2,004<br>24,711<br>71,681<br>18,167<br>17,123<br>106,971<br>53,642<br>19,183<br>13,248<br>86,073<br>65,739<br>40,620<br>16,161<br>122,520<br>68,032<br>40,214<br>12,504<br>120,750<br>48,343<br>12,546<br>5,785<br>66,674<br>48,232<br>12,180<br>4,476<br>64,888|
|---|---|
||4,319,945<br>292,596<br>117,920<br>4,730,461<br>4,053,603<br>291,536<br>91,236<br>4,436,375<br>246,765<br>77,960<br>26,180<br>350,905<br>192,558<br>74,575<br>20,255<br>287,388<br>17,426<br>16,542<br>4,529<br>38,497<br>10,769<br>16,128<br>3,504<br>30,401<br>70,672<br>12,191<br>6,467<br>89,330<br>41,606<br>12,601<br>5,004<br>59,211|
||334,863<br>106,693<br>37,176<br>478,732<br>244,933<br>103,304<br>28,763<br>377,000|
||4,654,808<br>399,289<br>155,096<br>5,209,193<br>4,298,536<br>394,840<br>119,999<br>4,813,375|



31 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **Charity** 

|**a) Activity**<br>Programmes<br>Research<br>Advocacy<br>Education<br>Leprosy<br>Review<br>**Charitable**<br>**Activities**<br>Database<br>Fundraising<br>Events<br>Institutions &<br>Trusts<br>Cost of<br>Generating<br>Funds<br>Total<br>Expenditure|**Direct**<br>**Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2024**<br>**Direct Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2023**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,804,969<br>207,857<br>76,261<br>2,089,087<br>1,747,752<br>206,346<br>59,004<br>2,013,102<br>9,021<br>13,406<br>2,590<br>25,017<br>9,094<br>13,613<br>2,004<br>24,711<br>71,681<br>18,167<br>17,123<br>106,971<br>53,642<br>19,183<br>13,248<br>86,073<br>65,739<br>40,620<br>16,161<br>122,520<br>68,032<br>40,214<br>12,504<br>120,750<br>48,343<br>12,546<br>5,785<br>66,674<br>48,232<br>12,180<br>4,476<br>64,888|
|---|---|
||1,999,753<br>292,596<br>117,920<br>2,410,269<br>1,926,752<br>291,536<br>91,236<br>2,309,524<br>246,765<br>77,960<br>26,180<br>350,905<br>192,558<br>74,575<br>20,255<br>287,388<br>17,426<br>16,542<br>4,529<br>38,497<br>10,769<br>16,128<br>3,504<br>30,401<br>70,672<br>12,191<br>6,467<br>89,330<br>41,606<br>12,601<br>5,004<br>59,211|
||334,863<br>106,693<br>37,176<br>478,732<br>244,933<br>103,304<br>28,763<br>377,000|
||2,334,616<br>399,289<br>155,096<br>2,889,001<br>2,171,685<br>394,840<br>119,999<br>2,686,524|



## **8  b) Analysis of central costs for apportionment** 

|Programmes<br>Research<br>Advocacy<br>Education<br>Leprosy Review<br>**Charitable Activities**<br>Database Fundraising<br>Events<br>Trust & Corporate<br>**Cost of Generating Funds**<br>**Total Expenditure**|**Office Costs**<br>**Depreciation**<br>**Total 2024**<br>**Total 2023**<br>**£**<br>**£**<br>**£**<br>**£**<br>52,818<br>23,443<br>76,261<br>59,004<br>1,794<br>796<br>2,590<br>2,004<br>11,859<br>5,264<br>17,123<br>13,248<br>11,193<br>4,968<br>16,161<br>12,504<br>4,007<br>1,778<br>5,785<br>4,476|
|---|---|
||81,671<br>36,249<br>117,920<br>91,236<br>18,132<br>8,048<br>26,180<br>20,255<br>3,137<br>1,392<br>4,529<br>3,504<br>4,479<br>1,988<br>6,467<br>5,004|
||25,748<br>11,428<br>37,176<br>28,763|
||107,419<br>47,677<br>155,096<br>119,999|



32 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

|**9**<br>**TANGIBLE FIXED ASSETS-**<br>**CONSOLIDATED**<br>**Cost**<br>1 April 2023<br>Additions<br>Disposals<br>Reclassification to<br>investment properties<br>31 March 2024<br>**Depreciation**<br>1 April 2023<br>Charged for year<br>Released on disposal<br>Reclassification to<br>investment properties<br>31 March 2024<br> <br>**Net book values**<br>1 April 2023<br>31 March 2024|**Land and**<br>**Premises**<br>**Overseas**<br>**Freehold Premises**<br>**UK**<br>**Motor**<br>**Vehicles**<br>**Office &**<br>**Photo**<br>**Equipment**<br>**Computer**<br>**Equipment**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>890,711<br>1,266,000<br>707,747<br>1,611,491<br>36,270<br>4,512,219<br>240,477<br>-<br>30,783<br>255,273<br>8,943<br>535,476<br>-<br>-<br>(17,653)<br>(93)<br>-<br>(17,746)<br>-<br>(69,369)<br>-<br>-<br>-<br>(69,369)|
|---|---|
||1,131,188<br>1,196,631<br>720,877<br>1,866,671<br>45,213<br>4,960,580<br>412,523<br>357,920<br>375,836<br>1,071,714<br>27,701<br>2,245,694<br>39,910<br>20,320<br>41,678<br>120,661<br>5,110<br>227,679<br>-<br>-<br>(13,899)<br>(85)<br>-<br>(13,984)<br>-<br>(16,552)<br>-<br>-<br>-<br>(16,552)|
||452,433<br>361,688<br>403,615<br>1,192,290<br>32,811<br>2,442,837<br>478,188<br>908,080<br>331,911<br>539,777<br>8,569<br>2,266,525|
||678,755<br>834,943<br>317,262<br>674,381<br>12,402<br>2,517,743|



33 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

|**TANGIBLE FIXED ASSETS**<br>**- CHARITY**<br>**Cost**<br>1 April 2023<br>Additions<br>Disposal<br>Reclassification to<br>investment properties<br>31 March 2024<br>**Depreciation**<br>1 April 2023<br>Charged for year<br>Released on disposal<br>Reclassification to<br>investment properties<br>31 March 2024<br>**Net book values**<br>1 April 2023<br>31 March 2024|**Freehold**<br>**Premises**<br>**UK**<br>**Motor**<br>**Vehicles**<br>**Office &**<br>**Photo Equip**<br>**Computer**<br>**Equipment**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,266,000<br>95,154<br>63,488<br>36,270<br>1,460,912<br>-<br>-<br>5,754<br>8,943<br>14,697<br>-<br>-<br>-<br>-<br>-<br>(69,369)<br>-<br>-<br>-<br>(69,369)|
|---|---|
||1,196,631<br>95,154<br>69,242<br>45,213<br>1,406,240<br>357,920<br>93,304<br>52,881<br>27,701<br>531,806<br>20,320<br>118<br>4,888<br>5,110<br>30,436<br>-<br>-<br>-<br>-<br>-<br>(16,552)<br>-<br>-<br>-<br>(16,552)|
||361,688<br>93,422<br>57,769<br>32,811<br>545,690<br>908,080<br>1,850<br>10,607<br>8,569<br>929,106|
||834,943<br>1,732<br>11,473<br>12,402<br>860,550|



34 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **INVESTMENT PROPERTY ASSETS – Charity and 10 Consolidated** 

|**INVESTMENT PROPERTY ASSETS – Charity and**<br>**Consolidated**||
|---|---|
|**Valuation**<br>1 April 2023<br>Reclassification from Tangible Fixed Assets<br>Revaluation<br>**31 March 2024**|**Consolidated**<br>**2024**<br>**Total**<br>**Charity**<br>**2024**<br>**Total**<br>**£**<br>**£**<br>214,715<br>214,715<br>52,817<br>52,817<br>16,238<br>16,238|
||283,770<br>283,770|



As at 31 March 2024, group investment properties were held at the revalued amount £283,770.  The revaluation was performed by Fenn Wright & Whybrow. 

**11 INTANGIBLE FIXED ASSETS – SOFTWARE** 

|**INTANGIBLE FIXED ASSETS – SOFTWARE**||
|---|---|
|**Cost**<br>1 April 2023<br>Additions<br>Disposals<br>31 March 2024<br>**Amortisation**<br>1 April 2023<br>Charged for year<br>Released on disposal<br>31 March 2024<br>**Net book values**<br>1 April 2023<br>31 March 2024|**Consolidated**<br>**2024**<br>**Consolidated**<br>**2023**<br>**Charity**<br>**2024**<br>**Charity**<br>**2023**<br>**£**<br>**£**<br>**£**<br>**£**<br>119,768<br>116,828<br>117,482<br>114,542<br>1,620<br>2,940<br>1,620<br>2,940<br>-<br>-<br>-<br>-|
||121,388<br>119,768<br>119,102<br>117,482<br>91,044<br>66,660<br>88,814<br>64,453<br>20,125<br>24,384<br>20,102<br>24,361<br>-<br>-<br>-<br>-|
||111,169<br>91,044<br>108,916<br>88,814<br>28,724<br>50,168<br>28,668<br>50,089|
||10,219<br>28,724<br>10,186<br>28,668|



35 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

|**12**<br>**FIXED ASSET INVESTMENTS**<br>At Market Value:<br>1 April 2023<br>Add: Additions<br>Less: Disposals in year<br>Net loss on revaluation<br>31 March 2024<br>Historical Cost at the 31 March 2024<br>The Investments are distributed as<br>follows:<br>UK Quoted investments<br>LEPRA India Investments<br>Unquoted Investments<br>31 March 2024|**Consolidated**<br>**Charity**<br>**2024**<br>**2023**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>**£**<br>**£**<br>68,874<br>69,312<br>42,418<br>44,019<br>-<br>1,163<br>-<br>-<br>-<br>-<br>-<br>-<br>(2,380)<br>(1,601)<br>(1,441)<br>(1,601)|
|---|---|
||66,494<br>68,874<br>40,977<br>42,418<br>38,719<br>39,658<br>13,202<br>13,202|
||18,735<br>20,176<br>18,735<br>20,176<br>25,517<br>26,456<br>-<br>-<br>22,242<br>22,242<br>22,242<br>22,242|
||66,494<br>68,874<br>40,977<br>42,418|



The unquoted investments are ordinary shares in Helpcards Holdings Ltd of which Lepra holds 6.74% of the issued share capital. 

36 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **13 ANALYSIS OF NET ASSETS** 

|**ANALYSIS OF NET ASSETS**||
|---|---|
|**Consolidated**<br>Restricted Funds<br>Designated Funds<br>Unrestricted Funds<br>**Charity**<br>Restricted Funds<br>Designated Funds<br>Unrestricted Funds|**2023/2024**<br>**Tangible**<br>**Fixed Assets**<br>**Intangible Assets**<br>**Net Current**<br>**Assets**<br>**Long Term**<br>**Liabilities**<br>**Investments**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>205,171<br>-<br>-<br>205,171<br>-<br>-<br>491,525<br>-<br>-<br>491,525<br>2,517,743<br>10,219<br>1,815,680<br>-<br>350,264<br>4,693,906|
||2,517,743<br>10,219<br>2,512,376<br>-<br>350,264<br>5,390,602|
||**Tangible**<br>**Intangible Assets**<br>**Net Current**<br>**Long Term**<br>**Investments**<br>**Total**<br>**Fixed Assets**<br>**Assets**<br>**Liabilities**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>23,429<br>-<br>-<br>23,429<br>-<br>-<br>491,526<br>-<br>-<br>491,526<br>860,550<br>10,186<br>621,129<br>-<br>324,747<br>1,816,612|
||860,550<br>10,186<br>1,136,084<br>-<br>324,747<br>2,331,567|



37 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **ANALYSIS OF NET ASSETS** 

## **Consolidated** 

## **2022/2023** 

|Restricted Funds<br>Designated Funds<br>Unrestricted Funds<br>**Charity**<br>Restricted Funds<br>Designated Funds<br>Unrestricted Funds|**Tangible**<br>**Intangible Assets**<br>**Net Current**<br>**Long Term**<br>**Investments**<br>**Total**<br>**Fixed Assets**<br>**Assets**<br>**Liabilities**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>187,528<br>-<br>-<br>187,528<br>-<br>-<br>550,548<br>-<br>-<br>550,548<br>2,266,525<br>28,724<br>2,405,548<br>-<br>283,589<br>4,984,386|
|---|---|
||2,226,525<br>28,724<br>3,143,624<br>-<br>283,589<br>5,722,462|
||**Tangible**<br>**Intangible Assets**<br>**Net Current**<br>**Long Term**<br>**Investments**<br>**Total**<br>**Fixed Assets**<br>**Assets**<br>**Liabilities**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>46,566<br>-<br>-<br>46,566<br>-<br>-<br>550,548<br>-<br>-<br>550,548<br>929,106<br>28,668<br>1,155,623<br>-<br>257,133<br>2,370,530|
||929,106<br>28,668<br>1,752,737<br>-<br>257,133<br>2,967,644|



38 



**Lepra** 

## **NOTES TO FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR END 31 MARCH 2024** 

|**14**<br>**STOCKS**<br>Stock<br>**15**<br>**DEBTORS**<br>Debtors & Prepayments<br>Sundry debtors<br>Amounts owed by group companies<br>Accrued income|**Consolidated**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>30,975<br>25,022<br>30,975<br>25,022<br>**Consolidated**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>425,260<br>282,493<br>3,019<br>13,152<br>-<br>-<br>21,366<br>114,423<br>449,645<br>410,068|**Charity**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>-<br>-|
|---|---|---|
|||-<br>-|
|||**Charity**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>78,426<br>34,171<br>3,019<br>13,152<br>20,083<br>36,537<br>21,366<br>114,423|
|||122,894<br>198,283|



All amounts included above are receivable within one year of the balance sheet date. Some of the amounts within Debtors above are financial instruments measured at present value. 

|**16**<br>**CREDITORS**<br>Due within one year<br>PAYE and other taxes<br>Accruals<br>Trade & Other Creditors<br>Deferred Income|**Consolidated**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>11,411<br>12,984<br>37,489<br>152,712<br>146,215<br>35,112<br>43,608<br>20,897<br>238,723<br>221,705|**Charity**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>11,411<br>12,984<br>37,489<br>152,712<br>42,774<br>19,642<br>43,608<br>20,897|
|---|---|---|
|||135,282<br>206,235|



Some of the amounts within creditors above are financial instruments measured at present value. Included within Other Creditors is an amount of £12,038 (2023: £4,256) relating to outstanding pension liabilities. 

Deferred income includes funding received for projects which commenced on 1 April 2023, analysed as follows: 

|Deferred income brought forward<br>Deferred in the year<br>Released in the year<br>Balance carried forward|**Consolidated**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>20,897<br>10,241<br>43,608<br>20,897<br>(20,897)<br>(10,241)<br>43,608<br>20,897|**Charity**<br>**2024**<br>**2023**<br>**£**<br>**£**<br>20,897<br>10,241<br>43,608<br>20,897<br>(20,897)<br>(10,241)|
|---|---|---|
|||43,608<br>20,897|



39 



**Lepra** 

## **NOTES TO FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR END 31 MARCH 2024** 

## **17a OPERATING LEASE COMMITMENTS** 

The following operating lease payments are committed to being paid over the following period: 

|period:|||||||
|---|---|---|---|---|---|---|
||**Consolidated**||||**Charity**||
||**2024**|**2023**||**2024**||**2023**|
||**£**|**£**||**£**||**£**|
|Leases expiring:|||||||
|Within one year||-|782||-|782|
|Between two and five years||-|-||-|-|
|After five years||-|-||-|-|



There was no expenditure processed through the SOFA relating to 2024 (2023 £5,089). 

## **17b OPERATING LEASE INCOME** 

The following operating lease payments are committed to being received over the following period: 

||**Consolidated**|**Consolidated**|**Charity**||
|---|---|---|---|---|
||**2024**|**2023**|**2024**|**2023**|
||**£**|**£**|**£**|**£**|
|Leases expiring:|||||
|Within one year|24,528|24,528|24,528|24,528|
|Between two and five years|24,528|46,332|24,528|46,332|
|After five years|-|-|-|-|



Income processed through the SOFA relating to the above lease was £24,528 for 2024 (2023 £20,475). 

40 



## L **epra** 

## **NOTES TO FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR END 31 MARCH 2024** 

|**18**<br>**UNRESTRICTED FUNDS**<br>**Consolidated**<br>1 April<br>Surplus /(Deficit) for the year<br>Realisation of investment revaluation gains (See note 2d)<br>Transfers between funds<br>(Loss)/ Gain on foreign currency transactions<br>Tax Provision Release BD<br>Corpus Fund<br>31 March<br>**Charity**<br>1 April<br>Surplus /(Deficit) for the year<br>Realisation of investment revaluation gains (See note 2d)<br>Transfers between funds<br>(Loss)/Gain on foreign currency transactions<br>31 March<br>**19**<br>**RESTRICTED FUNDS**<br>**LEPRA India**<br>1 April 2023<br>Incoming Resources<br>Resources Expended<br>31 March 2024<br>**Charity Restricted Funds**<br>1 April 2023<br>Incoming Resources<br>Resources Expended<br>Transfers between funds<br>31 March 2024<br>**Consolidated Total restricted funds**|**2024**<br>**£**<br>4,984,386<br>(235,089)<br>14,797<br>-<br>(70,188)<br>-<br>-<br>4,693,906<br>2,370,530<br>(534,164)<br>14,797<br>-<br>(34,550)<br>1,816,613<br>**2024**<br>**£**<br>140,962<br>1,315,334<br>1,456,296<br>(1,274,554)<br>181,742<br>46,566<br>351,421<br>397,987<br>(374,558)<br>-<br>23,429<br>205,171|**2023**<br>**£**<br>4,458,319<br>609,661<br>(1,601)<br>-<br>(81,993)<br>-<br>-|
|---|---|---|
|||4,984,386|
|||2,252,381<br>150,914<br>(1,601)<br>-<br>(31,164)|
|||2,370,530|
|||**2023**<br>**£**<br>120,586<br>1,272,567|
|||1,393,153<br>(1,252,191)|
|||140,962<br>49,155<br>405,472|
|||454,627<br>(408,061)<br>-|
|||46,566|
|||187,528|



41 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

|**NOTE 19 RESTRICTED FUNDS**<br>**(Continued)**<br>**India**<br>Lepra Society of India<br>**Charity**<br>ILEP India<br>ILEP Bangladesh<br>ILEP Leprosy Review<br>The Datum Foundation<br>St Lazarus Charitable Trust<br>The Anne,Ciara and Niamh Copeland<br>200 Club Trust Fund<br>Robert Luff<br>The Hodge Foundation<br>The Grace Trust<br>The Belpech Trust<br>S Temple Charitable Trust<br>Evan Cornish<br>**Total Charity**<br>**Total consolidated**|**Balance 1**<br>**April 2023**<br>**£**<br>140,962<br>**140,962**<br>16,375<br>20,664<br>3,002<br>-<br>-<br>-<br>1,929<br>-<br>-<br>-<br>-<br>4,596<br>**46,566**<br>**187,528**|**Incoming**<br>**Resources**<br>**£**<br>1,315,334<br>**1,315,334**<br>134,032<br>75,661<br>38,465<br>6,000<br>30,263<br>5,000<br>15,000<br>5,000<br>2,000<br>25,000<br>15,000<br>-<br>**351,421**<br>**1,666,755**|**Expenditure**<br>**Transfers**<br>**£**<br>**£**<br>(1,274,553)<br>-<br>**(1,274,553)**<br>**-**<br>(150,407)<br>-<br>(96,325)<br>-<br>(41,467)<br>-<br>(6,000)<br>-<br>(7,566)<br>-<br>(5,000)<br>-<br>(16,929)<br>-<br>(5,000)<br>-<br>(2,000)<br>-<br>(24,268)<br>-<br>(15,000)<br>-<br>(4,596)<br>-<br>**(374,558)**<br>**-**<br>**(1,649,112)**<br>**-**|**Balance**<br>**31**<br>**March**<br>**2024**<br>**£**<br>181,742<br>**181,742**<br>-<br>-<br>-<br>-<br>22,697<br>-<br>-<br>-<br>-<br>732<br>-<br>-|
|---|---|---|---|---|
|||||**23,429**|
|||||**205,171**|



42 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **NOTE 19 RESTRICTED FUNDS (Continued)** 

**Lepra Society India** - This includes funds raised in India from a variety of sources for work on specific projects. 

**Poverty reduction** through strengthened health systems in Bangladesh – HSS Project – TLM Canada (effect:hope) 

**ILEP Projects in India-** funding provided by members of the International Federation of Anti-Leprosy Association (ILEP) for projects in India. 

**ILEP Projects in Bangladesh-** funding provided by members of the International Federation of Anti-Leprosy Association (ILEP) for projects in Bangladesh. 

**ILEP Leprosy Review-** funding provided by members of the International Federation of Anti-Leprosy Association (ILEP) for production of Leprosy Review 

**Sonepur RC Refurbishment ,** - The Datum Foundation 

**Leprosy Related Disability Research Project-** Robert Luff Foundation 

## **M Mental Health Project -** St Lazarus Charitable Trust 

**Chai Project Moulvibazzar District, Bangladesh** - Supporting Tea Plantation worker to access health care and improve their quality of life - Baillie Gifford & Evan Cornish Trust 

**Upgrading the Footwear Manufacturing Unit, Bihar –** The Belpech Trust 

**Hydrabad Family Support –** The Belpech Trust 

**ACF Programme & POD Service Swabhiman. Odisha** - Active Leprosy case finding and supporting individuals to access the care and support available to them- Bryan Guinness Charitable Trust 

**Koraput Referral Unit, Odisha** - The Anne, Ciara and Niamh Copeland 200 Club Trust Fund 

43 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **NOTE 19 RESTRICTED FUNDS (Continued) 2022/23** 

|**NOTE 19 RESTRICTED FUNDS**<br>**(Continued)**<br>**India**<br>Lepra Society of India<br>ILEP in India<br>**Charity**<br>ILEP India<br>ILEP Bangladesh<br>ILEP Leprosy Review<br>Margaret Mcewen Trust<br>St Lazarus Charitable Trust<br>The Anne,Ciara and Niamh Copeland<br>200 Club Trust Fund<br>Robert Luff<br>Bryan Guinness Charitable Trust<br>Baillie Gifford<br>Evan Cornish<br>**Total Charity**<br>**Total consolidated**|**Balance 1**<br>**April 2022**<br>£<br>96,852<br>23,734<br>**120,586**<br>31,228<br>-<br>17,927<br>-<br>-<br>-<br>-<br>-<br>-<br>**49,155**<br>**169,741**|**Incoming**<br>**Resources**<br>£<br>1,113,404<br>139,163<br>**1,272,567**<br>140,726<br>172,960<br>33,312<br>300<br>15,174<br>6,000<br>10,000<br>2,000<br>20,000<br>5,000<br>**405,472**<br>**1,678,039**|**Expenditure**<br>**Transfers**<br>£<br>£<br>(1,215,205)<br>-<br>(36,986)<br>-<br>**(1,252,191)**<br>**-**<br>(155,579)<br>-<br>(152,296)<br>-<br>(48,237)<br>-<br>(300)<br>-<br>15,174<br>-<br>(6,000)<br>-<br>(8,071)<br>-<br>(2,000)<br>(20,000)<br>-<br>(404)<br>-<br>**(408,061)**<br>**-**<br>**(1,660,252)**<br>**-**|**Balance**<br>**31**<br>**March**<br>**2023**<br>£<br>15,051<br>125,911<br>**140,962**<br>16,375<br>20,664<br>3,002<br>-<br>-<br>-<br>1,929<br>-<br>4,596|
|---|---|---|---|---|
|||||**46,566**|
|||||**187,528**|



44 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

**YEAR ENDED 31 MARCH 2024** 

|**20**<br>**DESIGNATED FUNDS- CONSOLIDATED**<br>Aspire Project<br>Joint Strategic Plan<br>**DESIGNATED FUNDS- CHARITY**<br>Aspire Project<br>Joint Strategic Plan<br>**DESIGNATED FUNDS- CONSOLIDATED**<br>Aspire Project<br>Joint Strategic Plan<br>**DESIGNATED FUNDS- CHARITY**<br>Aspire Project<br>Joint Strategic Plan|**Balance**<br>**1 April 2023**<br>**£**<br>150,548<br>400,000<br>550,548<br>**Balance**<br>**1 April 2023**<br>**£**<br>150,548<br>400,000<br>550,548<br>**Balance**<br>**1 April 2022**<br>**£**<br>206,281<br>400,000<br>606,281<br>**Balance**<br>**1 April 2022**<br>**£**<br>206,281<br>400,000<br>606,281|**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-<br>**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-<br>**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-<br>**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-|**Expenditure**<br>**£**<br>(59,023)<br>-<br>(59,023)<br>**Expenditure**<br>**£**<br>(59,023)<br>-<br>(59,023)<br>**Expenditure**<br>**£**<br>(55,733)<br>-<br>(55,733)<br>**Expenditure**<br>**£**<br>(55,733)<br>-<br>(55,733)|**Balance**<br>**31 March**<br>**2024**<br>**£**<br>91,525<br>400,000|
|---|---|---|---|---|
|||||491,525|
|||||**Balance**<br>**31 March**<br>**2024**<br>**£**<br>91,525<br>400,000|
|||||491,525|
|||||**Balance**<br>**31 March**<br>**2023**<br>**£**<br>150,548<br>400,000|
|||||550,548|
|||||**Balance**<br>**31 March**<br>**2023**<br>**£**<br>150,548<br>400,000|
|||||550,548|



**Aspire Project -Integrating skin NTDs into the diagnosis and management of prevalent skin diseases.** A 5-year collaboration project with effect hope. The funds will be spent over the lifetime of the project. Please refer to Trustee report for further information. 

**Joint Strategic Plan (JSP)- Lepra’s Board have designated funds in order to complete the JSP** -Lepra’s Board have designated UK funds in order to complete the JSP – Lepra has been working internationally across the leprosy spectrum from transmission, through disability prevention and medical rehabilitation (DPMR) and advocacy for the duration of the JSP (20212024). The designation is to cover the additional costs of implementing the plan compared to the recurrent expenditure inherent in programme delivery. A significant deficit budget was approved by the board in 2024 for the delivery of the global strategy for 2024-29. 

45 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

|**21**<br>**ANALYSIS OF CHANGES IN NET DEBT**<br>Cash in hand and at bank at 1 April<br>Debt due < 1 year<br>Debt due > 1 year<br>Balance at 31 March<br>**ANALYSIS OF CHANGES IN NET DEBT**<br>Cash in hand and at bank at 1 April<br>Debt due < 1 year<br>Debt due > 1 year<br>Balance at 31 March<br>**22**<br>**ANALYSIS OF THE BALANCES OF CASH AND CASH**<br>**EQUIVALENTS**<br>Deposits with banks<br>Cash<br>**ANALYSIS OF THE BALANCES OF CASH AND CASH**<br>**EQUIVALENTS**<br>Deposits with banks<br>Cash|**CONSOLIDATED**<br>**1 April 2023**<br>**Non-Cash**<br>**Changes**<br>**Cashflow**<br>**31 March**<br>**2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>2,304,095<br>-<br>(664,958)<br>1,639,137<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|
|---|---|
||2,304,095<br>-<br>(664,958)<br>1,639,137|
||**CHARITY**<br>**1 April 2023**<br>**Non-Cash**<br>**Changes**<br>**Cashflow**<br>**31 March**<br>**2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,760,689<br>-<br>(612,217)<br>1,148,472<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|
||1,760,689<br>-<br>(612,217)<br>1,148,472|
||**Consolidated**<br>**1 April 2023**<br>**Movement**<br>**31 March 2024**<br>**£**<br>**£**<br>**£**<br>2,304,071<br>(664,958)<br>1,639,113<br>24<br>-<br>24|
||2,304,095<br>(664,958)<br>1,639,137|
||**Charity**<br>**1 April 2023**<br>**Movement**<br>**31 March 2024**<br>£<br>£<br>£<br>1,760,665<br>(612,217)<br>1,148,448<br>24<br>-<br>24|
||1,760,689<br>(612,217)<br>1,148,472|



46 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **23       EMPLOYEES** 

**The head count of employees during the year was as follows:** 

|**2024**<br>Head Office<br>21<br>Overseas<br>418<br>437<br>**The full-time equivalent head count of employee during the year was as follows:**<br>**2024**<br>Head Office<br>18<br>Overseas<br>418<br>434<br>The above excludes volunteers who provide their services free of charge.<br>**Staff costs in respect of employees during the year include:**<br>**Consolidated**<br>**2024**<br>£<br>Wages and salaries<br>1,949,168<br>Social security costs<br>63,046<br>Pension costs<br>62,337<br>Other staff costs<br>9,148<br>2,083,699<br>**Staff costs in respect of employees include:**<br>**Charity**<br>**2024**<br>£<br>Wages and salaries<br>936,998<br>Social Security<br>63,046<br>Pensions costs<br>62,337<br>Other staff costs<br>9,148<br>1,071,529|**2023**<br>20<br>403|
|---|---|
||423|
||**2023**<br>16<br>403|
||419|
||**2023**<br>£<br>2,020,711<br>56,144<br>46,056<br>8,593|
||2,131,504|
||**2023**<br>£<br>903,236<br>56,144<br>46,056<br>8,593|
||1,014,029|



47 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **23      EMPLOYEES (Continued)** 

||**2024**|**2023**|
|---|---|---|
|**The number of employees who received total emoluments in the following**|||
|**ranges was:**|||
|£60K to £69K|1|-|
|£70K to £79K|-|-|
|£80K-£89K|-|-|
|£90-99K|1|1|



The pension payments made to these higher paid employees amounted to £11,597 (£8,597 in 2023). 

The key management personnel of Lepra comprise the Trustees, Chief Executive, Director of Fundraising and Communications, Director of Resources and Director of Programmes & Advocacy in the UK, the Country Director, Head of Programmes, Head of Finance and Head of HR in Bangladesh and the Chief Executive Officer, Head of Finance and Head of Programmes in India. The employee remuneration of key management personnel for Lepra was £445,694 (2023 : £488,934), which includes £0 for compensation for loss of office (2023: £12,531). The Trustees received no remuneration for their services to the Organisation during the period (2023 £nil). During the period one (2023: 3) Trustee incurred expenses of £57 for travel, overseas travel, subsistence, and training courses (2023: £413). 

During 2024 there were redundancy payments of £Nil (2023: £0). However there was a £12,531 payment for the loss of office in 2023. 

## **24 PENSION COMMITMENTS** 

LEPRA provides pension benefits for staff by making contributions to a Group Personal Pension Plan. The employee is required to pay a minimum of 3% of their gross salary with the charity contributing 5-8% depending upon individual employment contracts.  The scheme complies with Auto Enrolment legislation. As at 31 March 2024 there were 25 staff (16 staff- 2023) who were members of this scheme. The cost of contributions are calculated annually and charged to the income and expenditure account as they arise. The costs for 2024 were £62,337 (2023: £46,056). 

48 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2024** 

## **25 COST OF AUDIT AND OTHER FINANCIAL SERVICES** 

|Amounts payable in respect of audit and other financial services were:<br>Auditors remuneration in respect of current year<br>Auditors remuneration in respect of prior year<br>Auditors remuneration in respect of non-audit services<br>**26**<br>**RELATED PARTIES**<br>Transactions with Lepra Society in India:<br>Amounts paid to Lepra Society<br>People's Lepra Foundation<br>Year end debtor balance|**2024**<br>**£**<br>33,399<br>12,708<br>1,309<br>47,416<br>**2024**<br>£<br>920,524<br>932<br>20,083|**2023**<br>**£**<br>25,408<br>29,789<br>2,690|
|---|---|---|
|||57,887|
|||**2023**<br>£<br>958,550<br>975<br>36,537|



People's Lepra Foundation is an incorporated company that is an independent not for profit set up by Lepra Society in 2021 to generate resources for support of organisations supporting people affected by Leprosy and Lymphatic Filariasis. Lepra society have a 98% holding in the company and there are 2 independent Directors as dictated by Indian law. 

49